Core Viewpoint - The stock of Valiant Biosciences-B (09887) rose over 5% following the announcement of the first patient enrollment in a Phase Ib/II clinical trial for LBL-024, a dual-specific antibody targeting PD-L1/4-1BB for the treatment of advanced melanoma [1] Group 1: Company Developments - Valiant Biosciences announced the successful enrollment of the first patient in the Phase Ib/II clinical trial (NCT07099430) for LBL-024, which will explore its use as a monotherapy or in combination for first-line treatment of advanced melanoma [1] - LBL-024 is noted as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally, with potential to become the first approved drug for advanced pulmonary neuroendocrine carcinoma [1] Group 2: Market Reaction - Following the announcement, Valiant Biosciences' stock price increased by 4.84%, reaching 65 HKD, with a trading volume of 22.107 million HKD [1] Group 3: Research and Development Focus - CMB International previously released a report highlighting Valiant Biosciences' focus on developing immunotherapies involving immune checkpoint inhibitors and co-stimulatory agonists, while also expanding into other areas such as CD3 T cell connectors and antibody-drug conjugates (ADC) [1] - The company has developed proprietary platforms, LeadsBody and X-body, which serve as engines for continuous drug discovery [1] - The firm is optimistic about the development of PD-L1/4-1BB and TCE as next-generation immuno-oncology therapies [1]
港股异动 | 维立志博-B(09887)午后涨超5% LBL-024黑色素瘤Ib/II期临床首例患者入组